<DOC>
	<DOCNO>NCT00795821</DOCNO>
	<brief_summary>The purpose study ass whether LY2216684 superior placebo treatment adult patient major depressive disorder .</brief_summary>
	<brief_title>A Study Adult Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Adults age 1865 year Meet criterion MDD define DSMIVTR criterion without psychotic feature Women childbearing potential must test negative pregnancy agree use reliable method birth control Grid Hamilton Rating Scale Depression ( GRIDHAMD17 ) total score &gt; =18 visit 1 visit 2 CGIS score &gt; =4 visit 1 visit 2 Are currently involve discontinue within last 30 day clinical trial involve offlabel use investigational drug Have previously complete withdrawn study study investigate LY2216684 Have currently additional ongoing DSMIVTR Axis 1 condition MDD Have anxiety disorder precede onset depression consider primary diagnosis within 1 year visit 1 Have Axis II disorder would interfere compliance protocol Have current previous diagnosis Bipolar I II , psychotic depression , schizophrenia psychotic disorder Have history substance abuse within past 1 year Women pregnant breastfeed Have lack response current depressive episode 2 adequate course antidepressant therapy , judgement investigator consider treatment resistant depression Patients judge serious suicidal risk Have serious unstable medical illness Have diagnose medical condition could exacerbate noradrenergic agent include unstable hypertension , unstable heart disease , tachycardia tachyarrhythmia , narrow angle glaucoma , urinary hesitation retention Have receive treatment MAOI within 14 day prior visit 1 Have history severe allergies 1 class medication multiple adverse drug reaction Have history electroconvulsive therapy ( ECT ) , transcranial magnetic stimulation ( TMS ) psychosurgery within last year Have history seizure disorder ( febrile seizure ) Require psychotropic medication sedative/hypnotic medication sleep Have thyroid stimulate hormone ( TSH ) level outside establish reference range . Are take received treatment exclude medication within 7 day prior visit 2 Initiation change intensity psychotherapy nondrug therapy within 6 week prior enrollment A positive urine drug screen substance abuse visit 1 Have initiate discontinue hormone therapy within previous 3 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>